Summary: A new longitudinal study shows that measuring brain iron with a specialized MRI method can predict cognitive decline and the development of mild cognitive impairment (MCI) years before clinical symptoms of Alzheimer’s disease appear. Researchers followed 158 cognitively healthy older adults and found that elevated iron levels in memory-related brain regions were linked to a higher risk of future cognitive impairment, particularly when amyloid pathology was also present.
The research suggests that quantitative susceptibility mapping (QSM) MRI — an advanced, noninvasive technique for mapping tissue magnetic susceptibility — could become a useful clinical tool for early detection, risk stratification, and potentially guiding treatments that target brain iron.
Key Facts
- Iron Detection: Quantitative susceptibility mapping (QSM) MRI provides precise, noninvasive measurement of brain iron.
- Risk Association: Higher iron levels in the entorhinal cortex and putamen predicted progression to mild cognitive impairment and faster cognitive decline.
- Dual Role: Brain iron may serve both as an early biomarker and as a possible therapeutic target to slow or prevent dementia.
Source: RSNA
A specialized MRI method that measures tissue magnetic susceptibility can identify elevated iron in specific brain regions and predict later cognitive decline, according to a study published in Radiology.
Alzheimer’s disease, the leading cause of dementia worldwide, develops over many years. Abnormal protein accumulations—amyloid beta and tau—begin to appear long before symptoms, and they can be detected with PET scans. However, treatments targeting amyloid and tau have shown only limited effectiveness, which has prompted researchers to investigate additional factors that may contribute to neurodegeneration and cognitive decline.
One such factor is elevated brain iron. Excess iron can promote neurodegeneration through mechanisms such as oxidative stress, increased toxicity of amyloid proteins, disruption of normal tau function, and neuronal damage. Quantifying iron in living brains has historically been challenging, but QSM MRI offers a reliable way to map and measure iron concentration across brain regions without invasive procedures.
“QSM is an advanced MRI technique developed over the last decade to measure tissue magnetic susceptibility with good precision,” said Xu Li, Ph.D., associate professor of radiology at Johns Hopkins University and research associate at the F.M. Kirby Research Center for Functional Brain Imaging at the Kennedy Krieger Institute, who served as the study’s senior author. “QSM can detect small differences in iron levels across brain regions, providing a reliable and noninvasive way to map and quantify iron in patients.”
The study examined 158 cognitively unimpaired participants from the Johns Hopkins BIOCARD Study, which focuses on early stages of Alzheimer’s disease and related disorders. PET amyloid data were available for 110 participants. Researchers collected baseline QSM MRI scans and followed participants for up to seven and a half years to track clinical outcomes and cognitive trajectories.
Results showed that higher baseline magnetic susceptibility — a proxy for increased iron — in the entorhinal cortex and the putamen, two regions involved in memory and cognition, was associated with an elevated risk of progressing to mild cognitive impairment. Participants with both higher iron levels and greater amyloid burden faced an even higher risk, suggesting that iron and amyloid pathology may interact to accelerate cognitive decline.
Although iron levels and amyloid burden each independently predicted progression to MCI, the study found synergistic effects when both were present, linked to faster global cognitive decline over time. These findings support the idea that combining biomarkers from different pathological pathways may improve early risk detection.
If validated in larger and more diverse study populations, QSM MRI could be integrated into clinical assessment protocols to identify individuals at high risk for dementia earlier in the disease course. Early identification can enable closer monitoring, enrollment in prevention trials, and timely application of emerging therapies.
“We can use this kind of tool to help identify patients at higher risk of developing Alzheimer’s disease and potentially guide early interventions as new treatments become available,” Dr. Li said. “Besides serving as a biomarker, brain iron may become a future therapeutic target.”
Future work will aim to clarify how brain iron interacts with other Alzheimer’s-related pathologies such as amyloid and tau, to standardize and speed up QSM acquisition for broader clinical use, and to evaluate iron-targeted therapies in clinical trials. Wider adoption of standardized QSM could help clinicians assess risk more accurately and tailor preventive strategies for individuals showing early signs of neurodegenerative change.
About this neurology and cognitive decline research news
Author: Linda Brooks
Source: RSNA
Contact: Linda Brooks – RSNA
Image: The image is credited to Neuroscience News
Original Research: The findings will appear in Radiology